A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB) (B-UNITED)
A Phase 2b, Multi-centre, Randomized, Partially Placebo-controlled, Double-blind Study to Investigate the Safety and Efficacy of Sequential Therapy With Daplusiran/Tomligisiran Followed by Bepirovirsen in Participants With Chronic Hepatitis B Virus on Background Nucleos(t)Ide Analogue Therapy (B-United)
Sponsor: GlaxoSmithKline
This PHASE2 trial investigates Chronic Hepatitis B Virus Infection and Hepatitis B and is currently ongoing. GlaxoSmithKline leads this study, which shows 5 recorded versions since 2024 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
5 versions recorded-
Sep 2025 — Present [monthly]
Active Not Recruiting PHASE2
-
Aug 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jun 2025 — Aug 2025 [monthly]
Recruiting PHASE2
-
Jan 2025 — Jun 2025 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Sep 2024 — Jan 2025 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Ansan, South Korea , Aracaju, Brazil , Athens, Greece , Auckland, New Zealand , Barcelona, Spain , Beijing, China , Bergamo, Italy , Berlin, Germany , Brussels, Belgium , Busan, South Korea and 59 more locations